Results 91 to 100 of about 19,143 (231)

Nipocalimab Dose Selection in Generalized Myasthenia Gravis

open access: yesCPT: Pharmacometrics &Systems Pharmacology, EarlyView.
Model‐Informed Nipocalimab Dose Selection for Generalized Myasthenia Gravis. ABSTRACT Nipocalimab is a fully human immunoglobulin G (IgG)1 monoclonal antibody (mAb) designed to selectively block the IgG binding site of neonatal fragment crystallizable receptor (FcRn) to inhibit IgG recycling and decrease circulating IgG, including pathogenic IgG ...
Belén Valenzuela   +8 more
wiley   +1 more source

Pharmacokinetic Model Selection for Personalized Infliximab Dosing in IBD

open access: yesCPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Infliximab, a monoclonal antibody used for immune‐mediated diseases, shows high interpatient pharmacokinetic variability. Prolonged exposure increases the risk of adverse effects and costs, making dose personalization essential to balance safety, efficacy, and cost‐effectiveness. Population pharmacokinetic models support individualized dosing,
Sahira Chaiben   +4 more
wiley   +1 more source

Novel Wide‐Spectrum Virucidal Lipid Nanoparticles

open access: yesSmall, EarlyView.
POSTAN is a novel broad‐spectrum antiviral nanoparticle that combines safety with potent virucidal activity. Composed of biocompatible lipids, it mimics heparan sulfate proteoglycans and lipid rafts exploited by viruses, thereby dismantling viral envelopes and blocking replication.
Yugo Araújo Martins   +10 more
wiley   +1 more source

Neonatal Fc receptor expression in lymphoid and myeloid cells in systemic lupus erythematosus [PDF]

open access: gold, 2020
Yanis Ramdani   +8 more
openalex   +1 more source

Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components

open access: yesSmall Methods, EarlyView.
The review presents a comprehensive overview of each component of lipid nanoparticles(LNPs)and their effects on editing efficiency. It specifically highlights strategies for achieving non‐liver delivery, aiming for broader applications in gene editing. Furthermore, this review summarizes the applications of LNPs in gene editing and offers insights for ...
Fan Wu   +6 more
wiley   +1 more source

A Qualitative Study on the Political Priority of Global Neurosurgery: An Emergent Global Health Network

open access: yesWorld Medical &Health Policy, EarlyView.
ABSTRACT This paper aimed to describe and analyze the factors that shaped the political priority of global neurosurgery from 2015 to 2022. The neurosurgery community formed a movement (that can be described as a global health network) to advocate for the neurosurgical patient to ensure safe, timely, and affordable neurosurgical care for all, and ...
Martina Gonzalez Gomez   +3 more
wiley   +1 more source

An engineered immunomodulatory IgG1 Fc suppresses autoimmune inflammation through pathways shared with i.v. immunoglobulin

open access: yesThe Journal of Clinical Investigation
Immunoglobulin G (IgG) antibodies in the form of high-dose intravenous immunoglobulin (IVIG) exert immunomodulatory activity and are used in this capacity to treat inflammatory and autoimmune diseases.
Sunny L. Sneed   +8 more
doaj   +1 more source

Reproductive Traits of Zoo‐Bred and Wild‐Bred Eastern Massasaugas (Sistrurus catenatus) at Species Survival Plan® Conservation Breeding Centres and Other Facilities

open access: yesZoo Biology, EarlyView.
Based on 94 Massasauga litters born in human care, mean litter size and number of live young per litter were higher in wild‐bred than in zoo‐bred litters. Wild‐bred litters more often contained live young than did zoo‐bred litters. In zoo‐bred litters, dam mass was positively associated with above‐average reproductive output.
Jonathan D. Choquette   +5 more
wiley   +1 more source

Economic Impact of Severe Early‐Onset Foetal Growth Restriction: A Multicentre Prospective Cohort Study

open access: yesBJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective Foetal growth restriction (FGR) affects 10% of pregnancies, contributing to 30% of stillbirths. Current management of early‐onset FGR (< 32 + 0 weeks' gestation) delivers the foetus before stillbirth or irreversible organ damage. The resulting preterm births create additional risks independent of FGR.
George Bray   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy